Provision Language
Definitions
“New Formulation” shall mean any Licensed Product that has not been approved for pediatric use as of the Effective Date.
AbbVie – MPP Agreement
8. Confidentiality and Publications
[…]
8.5 Publications. MPP agrees to provide AbbVie with a manuscript of any scientific publication or medical communication regarding a New Formulation, including but not limited to manuscripts, abstracts, posters, slides or other materials used for presentations (collectively, “Scientific Publication(s)”), at least ninety (90) days prior to presentation or submission thereof for publication. AbbVie reserves the right to review any such Scientific Publication and to require changes therein in order to protect its proprietary rights and interests in the Confidential Information. MPP agrees that it shall not present, publish nor submit any Scientific Publication without the prior approval of AbbVie, which approval shall not be unreasonably withheld.
Form of Sublicense
12. Confidentiality and Publications
[…]
12.2 Publications. Licensee agrees to provide Licensor and AbbVie with a manuscript of any scientific publication or medical communication regarding a New Formulation, including but not limited to manuscripts, abstracts, posters, slides or other materials used for presentations (collectively, “Scientific Publication(s)”), at least ninety (90) days prior to presentation or submission thereof for publication. Licensor and AbbVie reserve the right to review any such Scientific Publication and to require changes therein in order to protect their proprietary rights and interests in the Confidential Information. Licensee agrees that it shall not present, publish nor submit any Scientific Publication without the prior approval of Licensor and AbbVie, which approval shall not be unreasonably withheld.